LINCOCIN CAPSULE

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

LINCOMYCIN (LINCOMYCIN HYDROCHLORIDE)

Saadav alates:

PFIZER CANADA ULC

ATC kood:

J01FF02

INN (Rahvusvaheline Nimetus):

LINCOMYCIN

Annus:

500MG

Ravimvorm:

CAPSULE

Koostis:

LINCOMYCIN (LINCOMYCIN HYDROCHLORIDE) 500MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

LINCOMYCINS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0105826001; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2006-08-02

Toote omadused

PRODUCT MONOGRAPH
LINCOCIN
*
LINCOMYCIN INJECTION USP
300 MG/ML STERILE SOLUTION
LINCOMYCIN HYDROCHLORIDE CAPSULES USP
500 MG CAPSULES
ANTIBIOTIC
Pfizer Canada Inc
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of revision:
April 8, 2008
CONTROL NUMBER: 119402
*
TM Pharmacia & Upjohn Company LLC
Pfizer Canada Inc, Licensee
©
Pfizer Canada Inc 2008
2
LINCOCIN
*
LINCOMYCIN INJECTION USP
300 MG/ML STERILE SOLUTION
LINCOMYCIN HYDROCHLORIDE CAPSULES USP
500 MG CAPSULES
THERAPEUTIC CLASSIFICATION
ANTIBIOTIC
ACTION, CLINICAL PHARMACOLOGY
The mode of action of lincomycin hydrochloride is the inhibition of
protein synthesis by the inhibition of
the binding of aminoacyl sRNA to the messenger ribosome complex at the
50S ribosomal unit.
INDICATIONS AND CLINICAL USES
LINCOCIN (lincomycin hydrochloride) is indicated in the treatment of
serious infections due to sensitive
gram positive organisms (staphylococci, including
penicillinase-producing staphylococci, streptococci
and pneumococci) when the patient is intolerant of, or the organism
resistant to other appropriate
antibiotics.
LINCOCIN is indicated in the treatment of osteomyelitis, when the
causative organism has been found to
be sensitive to this antibiotic.
CONTRAINDICATIONS
As with all drugs, the use of LINCOCIN (lincomycin hydrochloride) is
contraindicated in patients
previously found to be hypersensitive to the drug or patients who have
previously been found
hypersensitive to clindamycin (Dalacin C) or to any other component of
the product.
3
LINCOCIN should not be given to persons with known pre-existing
monilial infections.
Until further clinical experience is obtained, LINCOCIN is not
indicated in the newborn.
WARNINGS
_Clostridium difficile_
-associated disease (CDAD) has been reported with use of many
antibacterial agents,
including LINCOCIN ( lincomycin hydrochloride). CDAD may range in
severity from mild diarrhoea to
fatal colitis. It is important to consider this diagnosis in patients
who present with diarrhoea, or symptoms
of colitis, pseudomembr